Shareholders' Equity (Tables)
|
12 Months Ended |
Jun. 30, 2026 |
|---|
| Shareholders' Equity [Abstract] |
|
| Schedule of Share Options Granted |
A summary of the share options granted
to non-employee consultants under the Plans by Pluri Inc. and Pluri Biotech is as follows:
| |
|
Year ended June 30, 2025 |
|
| |
|
Number |
|
|
Weighted
average
exercise price |
|
|
Weighted
average
remaining
contractual
terms
(in years) |
|
|
Aggregate
intrinsic
value price |
|
| Share options outstanding at beginning of period |
|
|
17,475 |
|
|
$ |
5.80 |
|
|
|
4.87 |
|
|
$ |
42 |
|
| Share options forfeited |
|
|
(6,720 |
) |
|
$ |
5.10 |
|
|
|
- |
|
|
|
- |
|
| Share options outstanding at end of the period |
|
|
10,755 |
|
|
$ |
6.23 |
|
|
|
4.23 |
|
|
$ |
24 |
|
| Share options vested and exercisable at the
end of the period |
|
|
10,755 |
|
|
$ |
6.23 |
|
|
|
4.23 |
|
|
$ |
24 |
|
| |
|
Year ended June 30, 2026 |
|
| |
|
Number |
|
|
Weighted
average
exercise price |
|
|
Weighted
average
remaining
contractual
terms
(in years) |
|
|
Aggregate
intrinsic
value price |
|
| Share options outstanding at beginning of period |
|
|
10,755 |
|
|
$ |
6.23 |
|
|
|
4.23 |
|
|
$ |
24 |
|
| Share options exercised |
|
|
(1,375 |
) |
|
$ |
- |
|
|
|
- |
|
|
|
6 |
|
| Share options outstanding at end of the period |
|
|
9,380 |
|
|
$ |
7.14 |
|
|
|
3.46 |
|
|
$ |
7 |
|
| Share options vested and exercisable at the
end of the period |
|
|
9,380 |
|
|
$ |
7.14 |
|
|
|
3.46 |
|
|
$ |
7 |
|
A summary of the share options granted
to CEO and to a former directors under the Plans by Pluri Inc. and Pluri Biotech is as follows:
| |
|
Year ended June 30, 2025 |
|
| |
|
Number |
|
|
Weighted
average
exercise price |
|
|
Weighted
average
remaining
contractual
terms
(in years) |
|
| Share options outstanding at the beginning of the period |
|
|
240,291 |
|
|
$ |
14.82 |
|
|
|
2.42 |
|
| Share options outstanding at the end of the period |
|
|
240,291 |
|
|
$ |
14.82 |
|
|
|
1.42 |
|
| Share options vested and exercisable at the end of the period |
|
|
240,291 |
|
|
$ |
14.82 |
|
|
|
1.42 |
|
| |
|
Year ended June 30, 2026 |
|
| |
|
Number |
|
|
Weighted
average
exercise price |
|
|
Weighted
average
remaining
contractual
terms
(in years) |
|
| Share options outstanding at the beginning of the period |
|
|
240,291 |
|
|
$ |
14.82 |
|
|
|
1.42 |
|
| Share options granted |
|
|
39,050 |
|
|
$ |
5.00 |
|
|
|
2.29 |
|
| Share options expired |
|
|
(114,676 |
) |
|
$ |
15.24 |
|
|
|
- |
|
| Share options outstanding at the end of the period |
|
|
164,665 |
|
|
$ |
12.20 |
|
|
|
1.02 |
|
| Share options vested and exercisable at the end of the period |
|
|
164,665 |
|
|
$ |
12.20 |
|
|
|
1.02 |
|
|
| Schedule of Black-Scholes Option-Pricing Model Using the Following Assumptions |
The fair value of each option was
estimated as of the date of grant using the Black-Scholes option-pricing model using the following assumptions:
| |
|
2026 |
|
| Underlying value of common shares ($) |
|
|
4.39 |
|
| Exercise price ($) |
|
|
5.00 |
|
| Expected volatility (%) |
|
|
76.40 |
|
| Expected terms of the option (years) |
|
|
3 |
|
| Risk-free interest rate (%) |
|
|
3.52 |
|
| Expected dividend yield (%) |
|
|
0 |
|
|
| Schedule of Activity Related to RSUs |
The following table summarizes the
activity related to unvested RSUs granted to employees and directors under the Plans by Pluri Inc. and Pluri Biotech, for the years ended
June 30, 2026 and 2025:
| |
|
Year ended June 30, |
|
| |
|
2026 |
|
|
2025 |
|
| |
|
Number |
|
| Unvested at the beginning of period |
|
|
634,763 |
|
|
|
353,134 |
|
| Granted |
|
|
130,313 |
|
|
|
618,515 |
|
| Forfeited |
|
|
(53,105 |
) |
|
|
(29,018 |
) |
| Vested |
|
|
(441,769 |
) |
|
|
(307,868 |
) |
| Unvested at the end of the period |
|
|
270,202 |
|
|
|
634,763 |
|
| Expected to vest after the end of period |
|
|
251,014 |
|
|
|
583,844 |
|
The following table summarizes the
activity related to unvested RSUs and RS granted to non-employee consultants under the Plans by Pluri Inc. and Pluri Biotech for the years
ended June 30, 2026 and 2025:
| |
|
Year ended June 30, |
|
| |
|
2026 |
|
|
2025 |
|
| |
|
Number |
|
| Unvested at the beginning of period |
|
|
24,551 |
|
|
|
4,802 |
|
| Granted |
|
|
205,941 |
|
|
|
54,269 |
|
| Forfeited |
|
|
(9,811 |
) |
|
|
- |
|
| Vested |
|
|
(198,931 |
) |
|
|
(34,520 |
) |
| Unvested at the end of the period |
|
|
21,750 |
|
|
|
24,551 |
|
| Expected to vest after the end of period |
|
|
21,750 |
|
|
|
24,551 |
|
|
| Schedule of Expenses Related to RSUs and RS Granted |
Total compensation expenses related
to RSUs and RS granted by Pluri Inc. and Pluri Biotech were recorded as follows:
| |
|
Year ended June 30, |
|
| |
|
2026 |
|
|
2025 |
|
| Research and development expenses |
|
$ |
345 |
|
|
$ |
463 |
|
| General and administrative expenses |
|
|
1,689 |
|
|
|
1,517 |
|
| |
|
$ |
2,034 |
|
|
$ |
1,980 |
|
|
| Schedule of Warrants and Options |
| e. |
Summary
of the Company’s warrants and options: |
| |
|
June 30, 2026 |
|
| Warrants / Options |
|
Weighted average exercise
price per
share |
|
|
Options and
warrants
for common
shares |
|
|
Options
and
warrants
exercisable
for common
shares |
|
|
Weighted
average
remaining
contractual
terms
(in years) |
|
| Warrants: |
|
$ |
8.24 |
|
|
|
214,783 |
|
|
|
214,783 |
|
|
|
0.13 |
|
| |
|
$ |
8.40 |
|
|
|
110,940 |
|
|
|
110,940 |
|
|
|
0.06 |
|
| |
|
$ |
5.57 |
|
|
|
84,599 |
|
|
|
84,599 |
|
|
|
2.00 |
|
| |
|
$ |
5.57 |
|
|
|
45,553 |
|
|
|
45,553 |
|
|
|
1.72 |
|
| |
|
$ |
4.25 |
|
|
|
312,500 |
|
|
|
312,500 |
|
|
|
1.25 |
|
| |
|
$ |
4.25 |
|
|
|
312,500 |
|
|
|
312,500 |
|
|
|
1.31 |
|
| Total warrants |
|
|
|
|
|
|
1,080,875 |
|
|
|
1,080,875 |
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Options: |
|
$ |
7.14 |
|
|
|
9,380 |
|
|
|
9,380 |
|
|
|
3.46 |
|
| |
|
$ |
8.96 |
|
|
|
20,927 |
|
|
|
20,927 |
|
|
|
0.15 |
|
| |
|
$ |
12.48 |
|
|
|
31,250 |
|
|
|
31,250 |
|
|
|
0.25 |
|
| |
|
$ |
16.64 |
|
|
|
31,250 |
|
|
|
31,250 |
|
|
|
0.25 |
|
| |
|
$ |
20.80 |
|
|
|
31,250 |
|
|
|
31,250 |
|
|
|
0.25 |
|
| |
|
$ |
6.08 |
|
|
|
10,938 |
|
|
|
10,938 |
|
|
|
4.73 |
|
| |
|
$ |
5.00 |
|
|
|
39,050 |
|
|
|
39,050 |
|
|
|
2.29 |
|
| Total options |
|
|
|
|
|
|
174,045 |
|
|
|
174,045 |
|
|
|
|
|
| Total Warrants and Options |
|
|
|
|
|
|
1,254,920 |
|
|
|
1,254,920 |
|
|
|
|
|
|